Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/ki.2015.233 http://scihub22266oqcxt.onion/10.1038/ki.2015.233 C4650264!4650264!26221753     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26221753&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Kidney+Int 2015 ; 88 (6): 1314-22 Nephropedia Template TP {{tp|p=26221753|t=2015. An extended mini-complement factor H molecule ameliorates experimental C3 glomerulopathy |pdf=|usr=}}{{26221753}} gab.com Text An extended mini-complement factor H molecule ameliorates experimental C3 glomerulopathy JO: Kidney Int http://www.kidney.de/pget.php?&tw=1&pmid=26221753 #FOAvip Abnormal regulation of the complement alternative pathway is associated with C3 glomerulopathy. Complement factor H is the main plasma regulator of the alternative pathway and consists of 20 short consensus repeat (SCR) domains. Although recombinant full-length factor H represents a logical treatment for C3 glomerulopathy, its production has proved challenging. We and others have designed recombinant mini-factor H proteins in which ?non-essential' SCR domains have been removed. Here, we report the in vitro and in vivo effects of a mini-complement factor H protein, FH1?5^18?20, using the unique factor H?deficient (Cfh?/?) mouse model of C3 glomerulopathy. FH1?5^18?20 is comprised of the key complement regulatory domains (SCRs 1?5) linked to the surface recognition domains (SCRs 18?20). Intraperitoneal injection of FH1?5^18?20 in Cfh?/? mice reduced abnormal glomerular C3 deposition, similar to full-length factor H. Systemic effects on plasma alternative pathway control were comparatively modest, in association with a short half-life. Thus, FH1?5^18?20 is a potential therapeutic agent for C3 glomerulopathy and other renal conditions with alternative pathway-mediated tissue injury. Twit Text FOAVip An extended mini-complement factor H molecule ameliorates experimental C3 glomerulopathy ????Kidney Int http://www.kidney.de/pget.php?&tw=1&pmid=26221753 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26221753 #FOAvip English Wikipedia <ref>{{Cite pmid|26221753}}</ref> An extended mini-complement factor H molecule ameliorates experimental C3 glomerulopathy #MMPMID26221753 Nichols EM; Barbour TD; Pappworth IY; Wong EKS; Palmer JM; Sheerin NS; Pickering MC; Marchbank KJ Kidney Int 2015[Dec]; 88 (6): 1314-22 PMID26221753show ga Abnormal regulation of the complement alternative pathway is associated with C3 glomerulopathy. Complement factor H is the main plasma regulator of the alternative pathway and consists of 20 short consensus repeat (SCR) domains. Although recombinant full-length factor H represents a logical treatment for C3 glomerulopathy, its production has proved challenging. We and others have designed recombinant mini-factor H proteins in which ?non-essential' SCR domains have been removed. Here, we report the in vitro and in vivo effects of a mini-complement factor H protein, FH1?5^18?20, using the unique factor H?deficient (Cfh?/?) mouse model of C3 glomerulopathy. FH1?5^18?20 is comprised of the key complement regulatory domains (SCRs 1?5) linked to the surface recognition domains (SCRs 18?20). Intraperitoneal injection of FH1?5^18?20 in Cfh?/? mice reduced abnormal glomerular C3 deposition, similar to full-length factor H. Systemic effects on plasma alternative pathway control were comparatively modest, in association with a short half-life. Thus, FH1?5^18?20 is a potential therapeutic agent for C3 glomerulopathy and other renal conditions with alternative pathway-mediated tissue injury. äAn extended mini-complement factor H molecule ameliorates experimental(epmc).pdf DeepDyve Pubget Overpricing